Jul. 18 at 3:04 PM
$RMD
After digging into ResMed (
$RMD), I think the market may be underestimating one structural risk.
It's not Philips.
It's not pricing pressure.
It's GLP-1 drugs.
If fewer people develop severe sleep apnea because of sustained weight loss, that's fewer future CPAP customers and fewer years of recurring supply revenue.
The installed base looks solid today, but the future patient funnel could be getting smaller.
In this week's Resilient Trader Trade Idea, I break down the thesis and the defined-risk bear put spread I'm using to express it.
$RMD $LLY $NVO
https://www.theresilienttrader.com/p/the-silent-threat-to-resmed-rmd
